Objective: Base on literature review, ertapenem induced seizure was scarce. This research investigated the relationship between the ertapenem-associated seizure and underlying diseases, thereby establishing prevention mechanisms.

Methods: We performed a retrospective chart review for patients who were received at least one dose of ertapenem before seizure episode during the hospital course from November 1, 2008 to July 31, 2015 and were notified to the adverse drug reaction information system.Results: Chart reviews for 14 patients were conducted. The mean age of the study population was 62.7 ± 14.7 years and 50% of the patients were male. The Naranjo Adverse Drug Reaction Probability Scale fall in the score between 3 and 5 and revealed a causality relationship graded as “possible” in two episodes and “probable” in the remaining twelve episodes. Ten patients (71.4%) had CNS disorders, 2 of whom had taken anticonvulsants and one of whom had a seizure. According to patients’ renal function reports, the number of patients with creatinine clearance (CrCl) ≤ 30 ml/min was seven (50%). The average time of the onset of seizures was 5.7 ± 3.7 days (ranging from 1 to 15 days) after the start of therapy. 
Conclusions: The incidence of seizure complicated due to ertapenem was very low. Nevertheless, clinicians should be vigilant regarding the possibility of ertapenem associated seizure, especially administering it to patients with elder, central nervous system (CNS) disorders, or patients with renal dysfunctions.